Advanced search
Publication Cover
Pharmacogenomics and Personalized Medicine Volume 16, 2023 - Issue
Submit an article Journal homepage
184
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

LncRNA FOXD2-AS1 Increased Proliferation and Invasion of Lung Adenocarcinoma via Cell-Cycle Regulation

Yuan YuanDepartment of Cardiothoracic Surgery, Xinjiang Military Region General Hospital, Urumqi, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-6989-3084
ORCID Icon,
Peng YuDepartment of Cardiothoracic Surgery, Xinjiang Military Region General Hospital, Urumqi, People’s Republic of China
,
Huihua ShenDepartment of Cardiothoracic Surgery, Xinjiang Military Region General Hospital, Urumqi, People’s Republic of China
,
Guozhu XingDepartment of Cardiothoracic Surgery, Xinjiang Military Region General Hospital, Urumqi, People’s Republic of China
&
Wu LiDepartment of Cardiothoracic Surgery, Xinjiang Military Region General Hospital, Urumqi, People’s Republic of China
Pages 99-109 | Received 09 Nov 2022, Accepted 06 Jan 2023, Published online: 03 Feb 2023

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
  • Li C, Wang H, Jiang Y, et al. Advances in lung cancer screening and early detection. Cancer Biol Med. 2022;19(5):591–608. doi:10.20892/j.issn.2095-3941.2021.0690
  • Yang S, Huang Y, Zhao Q. Epigenetic alterations and inflammation as emerging use for the advancement of treatment in non-small cell lung cancer. Front Immunol. 2022;13:878740. doi:10.3389/fimmu.2022.878740
  • Nielsen AH, Fredberg U. Earlier diagnosis of lung cancer. Cancer Treat Res Commun. 2022;31:100561. doi:10.1016/j.ctarc.2022.100561
  • Ruparel M, Quaife SL, Dickson JL, et al. Lung screen uptake trial: results from a single lung cancer screening round. Thorax. 2020;75(10):908–912. doi:10.1136/thoraxjnl-2020-214703
  • Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–159. doi:10.1038/nrg2521
  • Huang W, Li H, Yu Q, et al. LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond. J Exp Clin Cancer Res. 2022;41(1):100. doi:10.1186/s13046-022-02319-z
  • Smolarz B, Zadrożna-Nowak A, Romanowicz H. The role of lncRNA in the development of tumors, including breast cancer. Int J Mol Sci. 2021;22(16):8427. doi:10.3390/ijms22168427
  • Hu Q, Tai S, Wang J. Oncogenicity of lncRNA FOXD2-AS1 and its molecular mechanisms in human cancers. Pathol Res Pract. 2019;215(5):843–848. doi:10.1016/j.prp.2019.01.033
  • Chang Y, Zhang J, Zhou C, et al. Long non-coding RNA FOXD2-AS1 plays an oncogenic role in hepatocellular carcinoma by targeting miR‑206. Oncol Rep. 2018;40(6):3625–3634.
  • Ghafouri-Fard S, Hussen BM, Gharebaghi A, Eghtedarian R, Taheri M. LncRNA signature in colorectal cancer. Pathol Res Pract. 2021;222:153432. doi:10.1016/j.prp.2021.153432
  • Liu Y, Zhang Y, Chen C, Li Y. lncRNA HIF1A-AS2: a potential oncogene in human cancers (Review). Biomed Rep. 2021;15(4):85. doi:10.3892/br.2021.1461
  • Yang X, Duan B, Zhou X. Long non-coding RNA FOXD2-AS1 functions as a tumor promoter in colorectal cancer by regulating EMT and notch signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(16):3586–3591.
  • Zhang QQ, Xu SL, Ding C, et al. LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression. Eur Rev Med Pharmacol Sci. 2021;25(2):678–686. doi:10.26355/eurrev_202101_24629
  • Xu TP, Wang WY, Ma P, et al. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer. Oncogene. 2018;37(36):5020–5036. doi:10.1038/s41388-018-0308-y
  • Hu Z, Huang L, Wang W, et al. Long non-coding RNA FOXD2-AS1 promotes proliferation, migration, and invasion in cholangiocarcinoma through regulating miR-760/E2F3 axis. Dig Dis Sci. 2022;67(2):546–558. doi:10.1007/s10620-021-06876-9
  • Zhuang SH, Meng CC, Fu JJ, Huang J. Long non-coding RNA ELFN1-AS1-mediated ZBTB16 inhibition augments the progression of gastric cancer by activating the PI3K/AKT axis. Kaohsiung J Med Sci. 2022;38(7):621–632. doi:10.1002/kjm2.12548
  • Yao Y, Liang Y, Dong X, et al. Association of long non-coding RNAs (lncRNAs) ANRIL and MALAT1 polymorphism with cervical cancer. Pharmgenomics Pers Med. 2022;15:359–375. doi:10.2147/PGPM.S358453
  • Gupta S, Hashimoto RF. Dynamical analysis of a boolean network model of the oncogene role of lncRNA ANRIL and lncRNA UFC1 in non-small cell lung cancer. Biomolecules. 2022;12(3):420. doi:10.3390/biom12030420
  • Xia H, Niu Q, Ding Y, et al. Long noncoding HOXA11-AS knockdown suppresses the progression of non-small cell lung cancer by regulating miR-3619-5p/SALL4 axis. J Mol Histol. 2021;52(4):729–740. doi:10.1007/s10735-021-09981-1
  • Cui J, Mo J, Luo M, et al. c-Myc-activated long non-coding RNA H19 downregulates miR-107 and promotes cell cycle progression of non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(10):12400–12409.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.